Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1

Tivantinib, a c-MET inhibitor, is investigated as a second-line treatment of HCC. It was shown that c-MET overexpression predicts its efficacy. Therefore, a phase-3 trial of tivantinib has been initiated to recruit “c-MET-high”patients only. However, recent evidence indicates that the anticancer act...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shuai, Török, Helga-Paula, Gallmeier, Eike, Kolligs, Frank T., Rizzani, Antonia, Arena, Sabrina, Göke, Burkhard, Gerbes, Alexander L., De Toni, Enrico N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673154/
https://www.ncbi.nlm.nih.gov/pubmed/26259250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673154/
https://www.ncbi.nlm.nih.gov/pubmed/26259250

Ejemplares similares